XLO Projected Dividend Yield
Xilio Therapeutics Inc ( NASDAQ : XLO )Xilio Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated immuno-oncology (I-O) therapies to improve cancer treatment outcomes without the systemic side effects of current I-O treatments. Using its proprietary platform, Xilio advances a pipeline of novel, tumor-activated clinical and preclinical I-O molecules, including cytokines, antibodies (bispecifics), and immune cell engagers. Its product pipeline features XTX101, XTX301, XTX202, XTX501, and other tumor-activated bispecific molecules and immune cell engagers, with XTX101 being an investigational anti-CTLA-4 monoclonal antibody. 20 YEAR PERFORMANCE RESULTS |
XLO Dividend History Detail XLO Dividend News XLO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |